Innate Pharma annual net profit margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma's net profit margin was −546.11% for fiscal 2025.
View full Innate Pharma company overview| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −546.11% | −300.24 pp |
| 2024 | 2024-12-31 | −245.87% | −233.59 pp |
| 2023 | 2023-12-31 | −12.28% | +88.46 pp |
| 2022 | 2022-12-31 | −100.74% | +113.03 pp |
| 2021 | 2021-12-31 | −213.78% | −122.07 pp |
| 2020 | 2020-12-31 | −91.70% | −67.51 pp |
| 2019 | 2019-12-31 | −24.19% | −27.44 pp |
| 2018 | 2018-12-31 | 3.25% | +113.13 pp |
| 2017 | 2017-12-31 | −109.88% | — |
Over the last five fiscal years, Innate Pharma's net profit margin decreased from −91.70% to −546.11%, a change of −454.40 percentage points.
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗